Get the Daily Brief
Latest Biotech News
Merck’s Oral Cholesterol Drug Clears Another Late-Stage Hurdle
Merck’s experimental oral cholesterol medication has passed another Phase 3 clinical trial, advancing toward regulatory approval and expanding treatment options in a class largely dominated by...
FDA Grants Priority Review to Boehringer's Oral HER2-Selective TKI Zongertinib
The FDA approved Zongertinib (Hernexeos®, BI 1810631) in August 2025 for unresectable or metastatic non-squamous non-small cell lung cancer (nSCLC) harboring HER2 mutations, granting priority...
Mercy BioAnalytics Raises $59M to Launch Ovarian Cancer Screening Test
Mercy BioAnalytics completed a $59 million Series B funding round, accelerating commercialization of its blood-based ovarian cancer test targeting post-menopausal women and assisting diagnosis of...
Wave Life Sciences’ RNA Editing Therapy Shows Proof of Concept in AATD
Wave Life Sciences released updated results from its ongoing Phase Ib/IIa trial of WVE-006, an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The data demonstrated durable...
Amgen Commits $600 Million to New Science and Innovation Center in California
Amgen announced a $600 million investment to construct a state-of-the-art Center for Science and Innovation at its Thousand Oaks global headquarters. The facility will consolidate...
Novartis and Arrowhead's $200 Million Parkinson’s RNAi Deal
Novartis has made a $200 million upfront investment to license Arrowhead Pharmaceuticals’ preclinical siRNA drug ARO-SNCA, targeting alpha-synuclein for Parkinson’s disease and other...
Mercy BioAnalytics Raises $59 Million to Launch Ovarian Cancer Screening Test
Mercy BioAnalytics secured $59 million in Series B funding to support the commercialization of its blood-based ovarian cancer screening tests set for initial rollout in 2026. The company's Halo...
Wave Life Sciences’ RNA Editing Therapy Shows Durable Activity but Investor Response Mixed
Wave Life Sciences released updated Phase Ib/IIa clinical data for its RNA editing oligonucleotide WVE-006 targeting alpha-1 antitrypsin deficiency (AATD). The results confirmed sustained...
Treeline Biosciences Surfaces With $1.1 Billion Raised and Three Cancer Drugs in Clinic
Treeline Biosciences, under the leadership of veteran drug hunters Josh Bilenker and Jeff Engelman, emerged from stealth announcing three oncology drug candidates entering clinical trials and a...
Ionis Pharmaceuticals’ Lipid-Lowering Drug Hits Phase 3 Goals, Plans Label Expansion
Ionis Pharmaceuticals announced that its antisense oligonucleotide drug Tryngolza met primary and secondary endpoints in two Phase 3 trials (Core and Core2) targeting severe hypertriglyceridemia....
United Therapeutics’ Inhaled Tyvaso Shows Surprising Phase 3 Win for Idiopathic Pulmonary Fibrosis
United Therapeutics reported unexpected positive results from a Phase 3 trial of nebulized Tyvaso (treprostinil) for idiopathic pulmonary fibrosis, a condition known for its limited treatment...
Advancements in AI for Precision Medicine and Biopharma Automation
Innovations continue to surge at the interface of artificial intelligence and biotech, with notable developments in AI-enhanced virtual cell models, antibody discovery platforms, and laboratory...
New Cancer Diagnostic and Imaging Technologies Gain Regulatory Clearance
Multiple diagnostic and imaging innovations advanced regulatory milestones augmenting cancer care. Geneseeq Technology received FDA 510(k) clearance for its GeneseeqPrime NGS Tumor Profiling Assay...
Amgen’s $600 Million Investment Elevates California Headquarters with New Innovation Center
Amgen announced plans to invest over $600 million into a state-of-the-art Center for Science and Innovation at its Thousand Oaks, California headquarters. Designed to integrate multidisciplinary...
Novartis Deepens Parkinson’s RNAi Bet with $200M Arrowhead License
Novartis has committed an upfront $200 million to Arrowhead Pharmaceuticals for exclusive rights to develop ARO-SNCA, a preclinical RNA interference therapy targeting alpha-synuclein, implicated...
Mercy BioAnalytics Secures $59M to Launch Ovarian Cancer Test
Supported by a $59 million Series B funding round, Mercy BioAnalytics intends to commercialize its blood-based ovarian cancer test in early 2026. Leveraging its Halo platform, which detects...
Wave Life Sciences Shows Proof of Concept for RNA Editing in AATD
Wave Life Sciences released updated clinical data from its phase Ib/IIa study for WVE-006, an RNA editing therapy aimed at alpha-1 antitrypsin deficiency (AATD). The data demonstrated sustained...
Amgen Commits $600M to New U.S. Science and Innovation Center
Amgen announced a $600 million investment to build a state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The new center aims to integrate...
Treeline Biosciences Raises Over $1.1B, Advances Multiple Cancer Drugs
Treeline Biosciences surfaced from stealth with disclosures of $200 million raised in a series A extension and announced three oncology drug candidates in clinical testing. The Massachusetts-based...
Precision Diagnostics: NeoGenomics Wins Patent Battle, Fuels MRD Commercialization
NeoGenomics secured a summary judgement invalidating key patents asserted by rival Natera, lifting an injunction that had halted commercialization of its Radar minimal residual disease (MRD)...